Eur Rev Med Pharmacol Sci 2020; 24 (10): 5193-5194
DOI: 10.26355/eurrev_202005_21297

Editorial – Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents

A. Izzi, V. Messina, L. Rinaldi, P. Maggi

Department of Infectious Disease and Emergency Infectious Diseases, D. Cotugno Hospital, Azienda Ospedaliera dei Colli, Naples, Italy. izziantonio@yahoo.it

Free PDF Download

To cite this article

A. Izzi, V. Messina, L. Rinaldi, P. Maggi
Editorial – Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 10
Pages: 5193-5194
DOI: 10.26355/eurrev_202005_21297

Keywords Related articles:

  1. Editorial – HCC in HCV patients and the direct acting antivirals: is there really a link?
  2. From SARS-CoV to SARS-CoV2: a potential guide to better understanding of pathophysiology of the disease and potential therapeutic modality
  3. Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries
  4. Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus
  5. Molecular modelling of the antiviral action of Resveratrol derivatives against the activity of two novel SARS CoV-2 and 2019-nCoV receptors